Project Details
Description
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination with CApecitabine for subjects with recurrent or treatment refractory metastatic Pancreatic Cancer (the RECAP trial)
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/11 → 8/30/16 |
Funding
- INCYTE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.